Indications -- Psoriasis/Chronic Inflammation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Indications -- Psoriasis/Chronic Inflammation

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Arthur Radley who wrote (382)	3/21/2003 11:09:28 AM
From: keokalani'nui	Read Replies (1) of 631

J&J arthritis drug combats psoriasis in study Friday March 21, 10:31 am ET SAN FRANCISCO, March 20 (Reuters) - Johnson & Johnson (NYSE:JNJ - News) on Friday said its arthritis drug Remicade improved symptoms of the skin disorder psoriasis in 88 percent of patients receiving the highest dose of the drug in a mid-stage trial. After 10 weeks, 88 percent of moderate to severe psoriasis patients treated with a higher dose of the drug -- 5 milligrams per kilogram of body weight -- achieved at least a 75 percent improvement in symptoms. At a lower dose of 3 mg per kg, 72 percent of patients saw at least a 75 percent improvement, according to the study. Results from the ongoing 249-patient Phase II study were presented in San Francisco on Friday at a meeting of the American Academy of Dermatology. snip The study's presenter, Dr. Kenneth Gordon, associate professor of medicine at Loyola University in Chicago, said Remicade, for which Phase III studies have not yet been launched, is still about three years away from being approved by regulators as a treatment for the skin disease.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next